Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).

---

ÖZGÜROĞLU M., Levy B. P., Horinouchi H., Yu J., Grainger E., Phuong P. H., ...More

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2023, (Summary Text)

• Publication Type: Conference Paper / Summary Text
• City: Illinois
• Country: United States Of America
• Istanbul University Affiliated: No